Bendectin and Birth Defects: The Challenges of Mass Toxic Substances Litigation
Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation, comparing individual and collective forms of litiga…
Mehr
CHF 45.90
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
V105:
Folgt in ca. 15 Arbeitstagen
Produktdetails
- ISBN: 978-0-8122-1645-5
- EAN: 9780812216455
- Produktnummer: 28194660
- Verlag: Univ Of Pennsylvania Pr
- Sprache: Englisch
- Erscheinungsjahr: 1998
- Seitenangabe: 384 S.
- Masse: H22.3 cm x B14.7 cm x D2.6 cm 581 g
- Auflage: Revised
- Gewicht: 581
Über den Autor
Michael D. Green is Professor of Law at the University of Iowa.
13 weitere Werke von Michael D. Green:
Bewertungen
Anmelden